Business
ImprimisRx’s FDA-Registered Outsourcing Facility Issued California License
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business,
About this update from Harrow, Inc.
[{"type":"text","content":"SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients. \n John Saharek, President of ImprimisRx, commented, “Our team is excited to begin serving our home state of California, and its nearly 40 million residents, with high-quality ophthalmic formulations from our FDA-registered 503B outsourcing facility. We are grateful the State of California has issued this permit, one that has been granted to only a select few of the outsourcing facilities registered with the FDA.” Mr. Saharek concluded, “The expected impact to ImprimisRx from this new license cannot be understated. While our business as a whole continues to grow nationally, we now expect California demand to significantly pick-up, and for California-specific sales to increase as a percentage of our overall revenue. This California 503B license is coming at a great time as recent investments we’ve made in automated equipment, personnel, and training are expected to increase our production capacity, easily allowing us to absorb the anticipated new demand. New or existing ImprimisRx customers interested in placing orders may click here. About ImprimisRx ImprimisRx is the nation’s leading ophthalmology-focused outsourcing facility and pharmaceutical compounding business, serving thousands of ophthalmologists and optometrists in all 50 states, with 40 proprietary ophthalmic formulations. ImprimisRx is headquartered in San Diego, CA and owns two FDA-inspected production and dispensing facilities in Ledgewood, New Jersey. There have been over three million eyes served by the formulations produced at these facilities. For more information about ImprimisRx, including ordering instructions, please visit our website, www.imprimisrx.com/. About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, in...